The Norwegian Coalition for Epidemic Preparedness Innovations (CEPI) has made a $4.9m investment in a Covid-19 vaccine consortium led by the Paris-based Institut Pasteur.
This is the eighth Covid-19 vaccine candidate in CEPI’s pipeline, as well as bringing the non-profit’s investment in tackling the ongoing global viral outbreak to $29.2m.
The consortium also includes Austrian biotech Themis and the University of Pittsburgh. Its candidate uses the measles vaccine virus as a vector, which allows the vaccine to deliver antigens directly into the parts of the immune system capable of memory response.
This approach was successfully used by Themis and the Institut Pasteur to develop against the severe acute respiratory syndrome (SARS)